Skip to main content

Invokana: MDL 2750

Invokana: MDL 2750

Invokana: MDL 2750

Introduction

Invokana: MDL 2750: In Re Invokana (Canagliflozin) Products Liability Litigation- created in December 2016, presided by Hon. Brian R. Martinotti, U.S.D.J, in the U.S. District Court for the District of New Jersey; First bellwether -September 2018. Cases are also filed in state courts, primarily in California, Pennsylvania, and New Jersey.  As per the most recent court records, more than 1,000 Invokana lawsuits are currently pending the federal MDL and are in the pretrial discovery phase.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Lawyers to Meet Nov. 5 for Talcum Powder Trial Prep

Categories: Talcum

As the first federal talcum powder bellwether trial approaches, both plaintiffs and defendants have finalized their legal teams and are preparing for a key pretrial conference scheduled for early November.

The upcoming proceedings mark a…

2025 Update: What to Know About PPI Lawsuit Settlements & Payout Dates

Categories: Settlements

Last updated on Oct 27, 2025.

The mass tort litigation involving proton pump inhibitor (PPI) drugs — such as Nexium, Prilosec, Prevacid and Protonix — is entering a pivotal phase in

New Front Emerges in Fight Against Synthetic Opioids

Categories: Opioids

The U.S. opioid crisis has already claimed hundreds of thousands of lives, with fentanyl standing out as one of the deadliest substances. Now the leading cause of death among Americans aged 18 to 44, fentanyl has become synonymous with overdose…

⏳ Save 80+ Hours Monthly — Try Medical Records Review for FREE!                     
💼 Delivered in 7 Days. No AI. No Contracts.
Handled by Certified Doctors — 100% Compliant.

Only 5 Free Slot remain — Offer Ends Soon!